US Patent

US8513202 — Crystalline form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate

Method of Use · Assigned to Mitsubishi Tanabe Pharma Corp · Expires 2027-12-03 · 2y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a novel crystalline form of a specific compound, characterized by its x-ray powder diffraction pattern and/or infra-red spectrum.

USPTO Abstract

A novel crystal form of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene hemihydrate, and having favorable characteristics, is characterized by its x-ray powder diffraction pattern and/or by its infra-red spectrum.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-493 — Invokana
U-2441 — Invokana
U-493 — Invokana
U-493 — Invokana
U-493 — Invokana
U-2632 — Invokana
U-493 — Invokana
U-493 — Invokana
U-2441 — Invokana
U-493 — Invokana

Patent Metadata

Patent number
US8513202
Jurisdiction
US
Classification
Method of Use
Expires
2027-12-03
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Mitsubishi Tanabe Pharma Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.